SOURCE: The Bedford Report

The Bedford Report

August 25, 2011 08:16 ET

Impressive Pipelines From Neoprobe and Ariad

The Bedford Report Provides Equity Research on Neoprobe and Ariad Pharmaceuticals

NEW YORK, NY--(Marketwire - Aug 25, 2011) - The importance of maintaining a steady pipeline of drugs to market is having varied effects on the biotechnology industry. Analysis by the professional services firm BDO argues that larger pharmaceutical firms are increasing reliance on biotech companies to fill their pipelines, which has been a net positive for small biotech companies. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investment research on Neoprobe Corporation (NYSE Amex: NEOP) and Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA). Access to the full company reports can be found at:

While the positive fundamentals are there, this month biotech stocks have suffered from what MarketWatch's Val Brickates Kennedy calls the "Dendreon Effect." The article reports that biotech companies whose stocks have taken heavy hits include those that are at early stages of marketing new treatments.

"Pretty much every company that had just launched a product or was about to launch a product got crushed," Leerink Swann analyst Howard Liang explains.

The Bedford releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Neoprobe is a biomedical company focused on enhancing oncology patient care and improving patient benefit. Neoprobe currently markets the Neoprobe GDS line of gamma detection systems that are widely used by cancer surgeons. Earlier this month the company submitted a New Drug Application for "Lymphoseek" to the U.S. Food and Drug Administration.

Recently, Ariad Pharmaceuticals, in partnership with Merck, announced positive results from a Phase 3 study of their sarcoma drug, ridaforolimus. Studies showed a 28 percent reduction in the risk of progression or death in those treated with ridaforolimus compared to placebo.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information